Last edition
News about "Roche treatment of spinal muscular atrophy (SMA) "
Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA)
Roche, announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdiplam with a decision expected by August 24, 2020
Roche Treatment Of Spinal Muscular Atrophy (SMA) | 13/04/2020 | By Darshana | 347
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members